William P Tansey

List of Publications by Year
in descending order

55 papers	5,036 citations	172457 29 h-index	161849 54 g-index
57 all docs	57 docs citations	57 times ranked	5470 citing authors

#	Article	IF	Citations
1	WIN site inhibition disrupts a subset of WDR5 function. Scientific Reports, 2022, 12, 1848.	3.3	10
2	Synergistic action of WDR5 and HDM2 inhibitors in SMARCB1-deficient cancer cells. NAR Cancer, 2022, 4, zcac007.	3.1	8
3	Discovery of Potent Orally Bioavailable WD Repeat Domain 5 (WDR5) Inhibitors Using a Pharmacophore-Based Optimization. Journal of Medicinal Chemistry, 2022, 65, 6287-6312.	6.4	15
4	Elevating SOX2 Downregulates MYC through a SOX2:MYC Signaling Axis and Induces a Slowly Cycling Proliferative State in Human Tumor Cells. Cancers, 2022, 14, 1946.	3.7	4
5	The SWI/SNF ATPase BRG1 facilitates multiple pro-tumorigenic gene expression programs in SMARCB1-deficient cancer cells. Oncogenesis, 2022, 11, .	4.9	5
6	MYC regulates ribosome biogenesis and mitochondrial gene expression programs through its interaction with host cell factorâ€“1. ELife, 2021, 10, .	6.0	45
7	Multiple interactions of the oncoprotein transcription factor MYC with the SWI/SNF chromatin remodeler. Oncogene, 2021, 40, 3593-3609.	5.9	14
8	Impact of WIN site inhibitor on the WDR5 interactome. Cell Reports, 2021, 34, 108636.	6.4	29
9	Drugging the â€œUndruggableâ€•MYCN Oncogenic Transcription Factor: Overcoming Previous Obstacles to Impact Childhood Cancers. Cancer Research, 2021, 81, 1627-1632.	0.9	25
10	Gene-specific quantification of nascent transcription following targeted degradation of endogenous proteins in cultured cells. STAR Protocols, 2021, 2, 101000.	1.2	1
11	Discovery and Structure-Based Optimization of Potent and Selective WD Repeat Domain 5 (WDR5) Inhibitors Containing a Dihydroisoquinolinone Bicyclic Core. Journal of Medicinal Chemistry, 2020, 63, 656-675.	6.4	33
12	Discovery of WD Repeat-Containing Protein 5 (WDR5)â€“MYC Inhibitors Using Fragment-Based Methods and Structure-Based Design. Journal of Medicinal Chemistry, 2020, 63, 4315-4333.	6.4	47
13	Targeting MYC through WDR5. Molecular and Cellular Oncology, 2020, 7, 1709388.	0.7	24
14	WDR5 is a conserved regulator of protein synthesis gene expression. Nucleic Acids Research, 2020, 48, 2924-2941.	14.5	40
15	Targeting WDR5: A WINning Anti-Cancer Strategy?. Epigenetics Insights, 2019, 12, 251686571986528.	2.0	25
16	Inhibition of MYC by the SMARCB1 tumor suppressor. Nature Communications, 2019, 10, 2014.	12.8	57
17	Displacement of WDR5 from Chromatin by a WIN Site Inhibitor with Picomolar Affinity. Cell Reports, 2019, 26, 2916-2928.e13.	6.4	70
18	Interaction of the oncoprotein transcription factor MYC with its chromatin cofactor WDR5 is essential for tumor maintenance. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 25260-25268.	7.1	69

#	Article	IF	Citations
19	Discovery and Optimization of Salicylic Acid-Derived Sulfonamide Inhibitors of the WD Repeat-Containing Protein 5â€“MYC Proteinâ€“Protein Interaction. Journal of Medicinal Chemistry, 2019, 62, 11232-11259.	6.4	40
20	Phosphorylation of XIAP at threonine 180 controls its activity in Wnt signaling. Journal of Cell Science, 2018, 131, .	2.0	11
21	Moonlighting with WDR5: A Cellular Multitasker. Journal of Clinical Medicine, 2018, 7, 21.	2.4	94
22	Discovery of Potent 2-Aryl-6,7-dihydro-5H-pyrrolo[1,2-a]imidazoles as WDR5-WIN-Site Inhibitors Using Fragment-Based Methods and Structure-Based Design. Journal of Medicinal Chemistry, 2018, 61, 5623-5642.	6.4	54
23	Interaction of Gcn4 with target gene chromatin is modulated by proteasome function. Molecular Biology of the Cell, 2016, 27, 2735-2741.	2.1	4
24	Interaction of MYC with host cell factor-1 is mediated by the evolutionarily conserved Myc box IV motif. Oncogene, 2016, 35, 3613-3618.	5.9	28
25	Antagonistic roles for the ubiquitin ligase Asr1 and the ubiquitin-specific protease Ubp3 in subtelomeric gene silencing. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 1309-1314.	7.1	6
26	A common functional consequence of tumor-derived mutations within c-MYC. Oncogene, 2015, 34, 2406-2409.	5.9	27
27	Interaction with WDR5 Promotes Target Gene Recognition and Tumorigenesis by MYC. Molecular Cell, 2015, 58, 440-452.	9.7	224
28	The MYCâ€“WDR5 Nexus and Cancer. Cancer Research, 2015, 75, 4012-4015.	0.9	52
29	Do changes in the c-MYC coding sequence contribute to tumorigenesis?. Molecular and Cellular Oncology, 2015, 2, e965631.	0.7	0
30	MYC and Chromatin. Open Access Journal of Science and Technology, 2015, 3, .	0.2	4
31	Mammalian MYC Proteins and Cancer. New Journal of Science, 2014, 2014, 1-27.	1.0	170
32	Functions of the Proteasome on Chromatin. Biomolecules, 2014, 4, 1026-1044.	4.0	31
33	The ubiquitin-selective chaperone Cdc48/p97 associates with Ubx3 to modulate monoubiquitylation of histone H2B. Nucleic Acids Research, 2014, 42, 10975-10986.	14.5	13
34	Ubiquitin and Proteasomes in Transcription. Annual Review of Biochemistry, 2012, 81, 177-201.	11.1	256
35	Letter to the Editor. Yeast, 2012, 29, 93-94.	1.7	7
36	Similar temporal and spatial recruitment of native 19S and 20S proteasome subunits to transcriptionally active chromatin. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 6060-6065.	7.1	49

#	Article	IF	Citations
37	Histone H2B ubiquitylation and H3 lysine 4 methylation prevent ectopic silencing of euchromatic loci important for the cellular response to heat. Molecular Biology of the Cell, 2011, 22, 2741-2753.	2.1	13
38	Proteolytic Instability and the Action of Nonclassical Transcriptional Activators. Current Biology, 2010, 20, 868-871.	3.9	22
39	Combined chemical and genetic approach to inhibit proteolysis by the proteasome. Yeast, 2010, 27, 965-974.	1.7	51
40	Damage control: DNA repair, transcription, and the ubiquitinâ€“proteasome system. DNA Repair, 2009, 8, 444-448.	2.8	57
41	Gal4 turnover and transcription activation. Nature, 2009, 461, E7-E7.	27.8	27
42	Adenovirus E1A targets p400 to induce the cellular oncoprotein Myc. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 6103-6108.	7.1	30
43	Modulation of RNA polymerase II subunit composition by ubiquitylation. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 19649-19654.	7.1	54
44	Myc-Mediated Transcriptional Repression by Recruitment of Histone Deacetylase. Cancer Research, 2008, 68, 3624-3629.	0.9	96
45	The proteasome: a utility tool for transcription?. Current Opinion in Genetics and Development, 2006, 16, 197-202.	3.3	234
46	A conserved element in Myc that negatively regulates its proapoptotic activity. EMBO Reports, 2005, 6, 177-183.	4.5	88
47	Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Nature, 2005, 436, 807-811.	27.8	419
48	The F Box Protein Dsg1/Mdm30 Is a Transcriptional Coactivator that Stimulates Gal4 Turnover and Cotranscriptional mRNA Processing. Cell, 2005, 120, 887-899.	28.9	155
49	The Proteasome Regulatory Particle Alters the SAGA Coactivator to Enhance Its Interactions with Transcriptional Activators. Cell, 2005, 123, 423-436.	28.9	165
50	Proteasomal ATPases Link Ubiquitylation of Histone H2B to Methylation of Histone H3. Molecular Cell, 2004, 13, 435-442.	9.7	186
51	How the ubiquitinâ€“proteasome system controls transcription. Nature Reviews Molecular Cell Biology, 2003, 4, 192-201.	37.0	725
52	Regulation of Transcriptional Activation Domain Function by Ubiquitin. Science, 2001, 293, 1651-1653.	12.6	346
53	Functional overlap of sequences that activate transcription and signal ubiquitin-mediated proteolysis. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 3118-3123.	7.1	248
54	Functional overlap of sequences that activate transcription and signal ubiquitin-mediated proteolysis. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 3118-3123.	7.1	135

#	Article	IF	Citations
55	Destruction of Myc by ubiquitin-mediated proteolysis: cancer-associated and transforming mutations stabilize Myc. EMBO Journal, 1999, 18, 717-726.	7.8	394